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2SYNOPSIS33
34
Liver mitochondrial ß-oxidation of long-chain fatty acid (LCFA) is tightly regulated35
through inhibition of carnitine palmitoyltransferase 1A (CPT1A) by malonyl-CoA, an36
intermediate of lipogenesis stimulated by glucose and insulin. Moreover, CPT1A sensitivity37
to malonyl-CoA inhibition varies markedly depending on the physio-pathological state of the38
animal. Here, we asked whether an increase in CPT1A activity solely or in association with a39
decreased malonyl-CoA sensitivity could, even in the presence of high glucose and insulin40
concentrations, maintain a sustained LCFA ß-oxidation and/or protect from triglyceride41
accumulation in hepatocytes. We showed that adenovirus-mediated expression of rat wild-42
type CPT1A (CPT1wt) and malonyl-CoA-insensitive CPT1AM593S mutant (CPT1mt) in43
cultured fed rat hepatocytes counteracted the inhibition of oleate ß-oxidation induced by 2044
mM glucose/10 nM insulin. Interestingly, the glucose/insulin-induced cellular triglyceride45
accumulation was prevented, both in the presence and absence of exogenous oleate. This46
resulted from the generation of a metabolic switch allowing ß-oxidation of de novo47
synthetised LCFA, which occured without alteration in glucose oxidation and glycogen48
synthesis. Moreover, CPT1mt expression was more effective than CPT1wt overexpression to49
counteract glucose/insulin effects, demonstrating that control of CPT1A activity by malonyl-50
CoA is an essential driving force for hepatic LCFA metabolic fate. In conclusion, this study51
highlights that CPT1A is a prime target to increase hepatic LCFA ß-oxidation and that acting52
directly on the degree of its malonyl-CoA sensitivity may be a relevant strategy to prevent53
and/or correct hepatic steatosis.54
55
56
57
58
Key words: carnitine palmitoyltransferase 1, mitochondria, fatty acid oxidation, lipogenesis,59
triglyceride, liver60
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3INTRODUCTION61
62
The hepatic isoform of carnitine palmitoyltransferase 1 (CPT1, EC 2.3.1.21) (CPT1A) is63
known to be the key regulatory enzyme in liver mitochondrial ß-oxidation of long-chain fatty64
acids (LCFA) [1,2]. By converting long-chain acyl-CoA (LC-CoA) to acylcarnitine, CPT1A65
catalyzes the rate-limiting step in the entry of cytosolic LC-CoA into mitochondria where ß-66
oxidation takes place. Under physiological conditions, lipogenesis and LCFA ß-oxidation are67
tightly regulated in the liver [1]. Malonyl-CoA, the first intermediate in lipogenesis, is68
synthetised by acetyl-CoA carboxylase (ACC) and is the substrate of fatty acid synthase69
(FAS) for de novo LCFA synthesis. Malonyl-CoA is also the physiological allosteric inhibitor70
of CPT1A [3]. Therefore, after feeding a carbohydrate-rich meal, the presence of both high71
plasma glucose and insulin concentrations stimulates liver glucose oxidation, glycogen72
storage and lipogenesis, allowing convertion of excess glucose to LCFA. The resulting73
increase in malonyl-CoA level inhibits CPT1A activity. Both exogenous LCFA taken up by74
the liver and endogenous LCFA generated by lipogenesis are then esterified into triglycerides75
(TG) and partly secreted as very-low-density lipoproteins (VLDL). Conversely, in the fasted76
state when lipogenesis is low, CPT1A is retrieved from malonyl-CoA inhibition. Hepatic ß-77
oxidation of LCFA released from adipose tissue can then occur to produce energy, cofactors78
required for optimal gluconeogenesis, and ketone bodies used as fuels by extrahepatic tissues79
[1,2].80
Disturbance of this key regulatory malonyl-CoA/CPT1A partnership might contribute to81
hepatic steatosis. Inherited CPT1A deficiency in humans is associated with hypoglycemia and82
hypoketonemia as well as hepatic steatosis during fasting [4,5]. Similarly to drug-induced83
impairment of mitochondrial ß-oxidation [6], pharmacological inhibition of CPT1A activity84
by irreversible inhibitors, such as tetradecylglycidic acid [7] or Etomoxir [8], induces85
mitochondrial injury leading to steatosis and inflammation. Whereas the consequences of a86
CPT1A activity defect are relatively known, the metabolic impact of an increased CPT1A87
activity per se had, until recently, never been reported in liver cells. During the meantime of88
our study was published that CPT1A overexpression in rat hepatocytes cultured in the89
presence of low glucose concentration increased LCFA ß-oxidation capacity, leading to90
metabolic reorientation of exogenous LCFA taken up by the cells toward oxidation at the91
expense of esterification [9]. However, whether such an increased capacity to oxidize92
exogenous LCFA could be maintained in conditions under which this pathway is usually93
abolished, e.g. in the presence of high glucose and insulin concentrations known to stimulate94
de novo lipogenesis [10], had never been investigated in any model. Moreover, a unique95
feature of CPT1A is that its sensitivity to malonyl-CoA inhibition varies markedly depending96
on physiological state in adult rat. For example, it is increased by refeeding carbohydrate to97
fasted rats, by obesity state or after insulin administration to diabetic rats, whereas it is98
decreased by starvation and diabetes [11-15].99
Thus, the aim of the present study was to clearly decipher whether a decrease in CPT1A100
malonyl-CoA sensitivity represents an efficient strategy to enhance mitochondrial LCFA ß-101
oxidation in liver cells. By overexpressing CPT1As with distinct malonyl-CoA sensitivity in102
cultured rat hepatocytes, we presently demonstrated that expression of a malonyl-CoA-103
insensitive CPT1A is more effective than overexpressing wild-type CPT1A to counteract104
glucose/insulin inhibitory effect on exogenous LCFA oxidation flux and to prevent105
glucose/insulin-induced TG accumulation. Moreover, modulation of the malonyl-106
CoA/CPT1A partnership generates a metabolic switch allowing ß-oxidation of de novo107
synthetised LCFA, hence preventing their esterification into TG. Altogether, these results108
highlight that control of CPT1A activity by malonyl-CoA is an essential driving force for109
hepatic LCFA metabolic fate and that acting directly on the degree of CPT1A malonyl-CoA110
Biochemical Journal Immediate Publication. Published on 20 Mar 2009 as manuscript BJ20081932
TH
IS
 IS
 N
O
T 
TH
E 
VE
RS
IO
N 
O
F 
RE
CO
RD
 - 
se
e 
do
i:1
0.
10
42
/B
J2
00
81
93
2
Ac
pte
d M
nu
sc
rip
t
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2009 The Authors Journal compilation © 2009 Portland Press Limited
4sensitivity may be a relevant strategy to prevent and/or reduce liver steatosis.111
112
113
EXPERIMENTAL114
115
Materials116
Collagenase used to isolate rat hepatocytes was purchased from Roche Diagnostics. Cell117
culture reagents (medium M199 with Earl salts, glutamine, Ultroser G) were obtained from118
Invitrogen. [14C]sodium bicarbonate was purchased from Perkin Elmer. [1-14C]oleate, D-[U-119
14
C]glucose, L-[methyl-3H]carnitine and [1-14C]acetate were purchased from GE Healthcare.120
5-(Tetradecyloxy)-2-furoic acid (TOFA) was a gift from Dr. A. Richardson (Merrel National121
Laboratories, Cincinnati, OH). TLC silica-plates and dexamethasone were purchased from122
Merck Chemicals. Insulin was obtained from Novo Nordisk. Other biochemicals were123
purchased from Sigma-Aldrich.124
125
Construction of recombinant adenovirus126
The CPT1AM593S mutant (CPT1mt) was constructed with the QuikChange site-directed127
mutagenesis kit (Stratagene) using pYeDP1/8–10 containing the full-length rat CPT1A cDNA128
[16] as template, and the forward 5’CCTCACATATGAGGCCTCCAGTACCCGGCTCTTC129
CGAGAAGG-3’ and reverse 5’CCTTCTCGGAAGAGCCGGGTACTGGAGGCCTCATAT130
GTGAGG-3’ primers. Human adenovirus serotype 5 vectors (Ad) encoding either -131
galactosidase (Ad-gal), wild-type rat CPT1A (Ad-CPT1wt) or CPT1mt (Ad-CPT1mt) under132
the control of the CMV promoter were produced by the Laboratoire de Thérapie Génique133
(INSERM U649, Nantes, France).134
135
Isolation of rat hepatocytes136
Male Wistar rats (200-300 g) were purchased from Elevage Janvier (France) and adapted to137
the environment for at least one week prior to the experiment. Rats were housed in plastic138
cages in a temperature-controlled (21°C) and ventilated room with a 12 h light-dark cycle139
(light from 3 p.m. to 3 a.m.). They had free access to water and were fed ad libidum a140
standard rodent chow (A03, SAFE). All procedures were carried out according to the French141
guidelines for the care and use of experimental animals, and were approved by the Direction142
départementale des services vétérinaires de Paris. Hepatocytes were isolated at 9 a.m. by143
collagenase perfusion into the portal vein as described previously [10]. Isolated hepatocytes144
were resuspended in M199 medium containing 5 mM glucose, penicillin (100 UI/ml),145
streptomycin (100 g/ml), 0.1% (w/v) BSA and 2 mM glutamine (basal medium). From cell146
attachment, whatever the experiments presently performed, 1 mM carnitine was147
systematically added to avoid a limitation in CPT1A activity which could alter LCFA148
oxidation. Cell viability estimated by tryptan blue exclusion was always greater than 80%.149
150
Hepatocyte culture and adenovirus infection151
Hepatocytes were plated at a density of 8 x 10
6
cells/100 mm petri dish (isolation of152
mitochondria), at 0.5 x 10
6
cells/well of 12-well plates (MTS assay) or at 2.5 x 10
6
cells/25153
cm
2
flask (other experiments) and cultured for 4 h at 37°C in an incubator equilibrated with154
air/CO2 (95:5) in basal medium supplemented with 100 nM dexamethasone, 10 nM insulin155
and 2% (v/v) Ultroser G before infection with adenovirus. After cell attachment, the medium156
was removed and hepatocytes were incubated for 2 h with 1 ml (flask), 250 l (12-well plate)157
or 3 ml (dish) of basal medium containing either 0, 2.5 or 5 infectious particles (ip)/cell of158
Ad-gal, Ad-CPT1wt or Ad-CPT1mt. Thereafter, the infection medium was removed and159
cells were further cultured for another 40 h, the experiments being performed during the last160
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524 h.161
162
Immunoblot analysis163
Aliquots of proteins were subjected to SDS/PAGE [17] in a 7% gel and transferred onto164
nitrocellulose membrane. Detection of proteins was performed as described previously [16]165
using the ECL Pierce detection system (Perbio Sciences SAS). The antibodies used were166
against rat CPT1A [16], E. coli -galactosidase (Rockland), rat FAS (gift from Dr. I. Dugail,167
INSERM U465, Paris, France), and human ACC2 (Upstate). For the generation of anti-CPT2168
polyclonal antibody, peptide corresponding to the last 20 C-terminal residues of human CPT2169
was synthesized, conjugated to keyhole limpet hemocyanin, and used to immunized New170
Zealand white rabbits (Neosystem). The immunoblots were quantified using a chemigenius171
apparatus (Syngene).172
173
Immunofluorescence assay174
Hepatocytes (7x10
5
cells/well of 6-well plates) were cultured on coverslips coated with 4%175
(v/v) collagen in 0.001% (v/v) acetic acid/PBS. Forty hours after infection (5 ip/cell), cells176
were fixed with 2% (v/v) formaldehyde, permeabilized with 0.1% (v/v) SDS and non-specific177
binding of antibodies was blocked by incubation with 10% (v/v) SVF/PBS for 20 min. Cells178
were stained with polyclonal anti-rat CPT1A and mouse monoclonal anti-cytochrome c (BD179
Biosciences) antibodies which were detected by a goat anti-rabbit IgG conjugated with180
Alexa® fluor 488 and a goat anti-mouse IgG conjugated with Alexa® fluor 594 (Molecular181
Probes), respectively. After incubation with 2 M Hoechst 33342 for DNA staining,182
coverslips were mounted on glass slides with fluoromount G (Clinisciences). Fluorescent183
staining was viewed in a confocal laser-scanning microscope (Leica TCS SP2 AOBS). The184
captured images were processed using ImageJ software (Wayne Rasband).185
186
Isolation of mitochondria and CPT activity assay187
Forty hours after infection, cells were washed and scraped with ice-cold PBS. Mitochondria188
were isolated in an isolation buffer (0.3 M sucrose, 5 mM Tris-HCl, 1 mM EGTA, pH 7.4)189
using differential centrifugation [16]. Protein concentration was determined by Lowry method190
using BSA as a standard [18]. CPT1 activity was assayed in intact isolated mitochondria as191
palmitoyl-L-[methyl-3H]carnitine formed from L-[methyl-3H]carnitine (400 M; 10 Ci/mol)192
and palmitoyl-CoA (600 M) in the presence of 1% (w/v) BSA. Estimation of the malonyl-193
CoA IC50 value (concentration of malonyl-CoA required for 50% inhibition) and CPT2194
activity were measured as described previously [16].195
196
Measurement of fatty acid metabolism197
During the last 24 h of culture, the medium was replaced by a medium containing either 5198
mM glucose or 20 mM glucose plus 10 nM insulin. Fatty acid oxidation and esterification199
were determined during the last 2 h of culture in the presence of 0.3 mM [1-14C]oleate (0.5200
Ci/mol) bound to 1% (w/v) defatted BSA. After 2 h of incubation, medium was collected to201
determine [14C]CO2, [14C]acid-soluble products (ASP), unlabeled ketone body production202
(acetoacetate and -hydroxybutyrate) and lactate and pyruvate concentrations. Cells were203
washed and scraped in PBS to determine [14C]triacylglycerol (TG) and [14C]phospholipid204
(PL) production as previously described [19,20]. For the determination of very-low-density205
lipoprotein (VLDL) secretion, medium (3 ml) was collected, immediately adjusted to 0.005%206
(w/v) gentamycin, 1 mM EDTA, 0.04% (w/v) sodium azide, and 0.02% (w/v) sodium207
(ethylomercurithio)-2 benzoate, and was layered under 5 ml of 0.15 M NaCl. After208
centrifugation at 100 000 g for 18 h at 10°C, the 1 ml top fraction containing VLDL was209
counted in 10 ml scintillation liquid in a scintillation counter (Packard).210
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6211
Measurement of intracellular TG and Oil red O staining212
For measurement of unlabeled TG, cellular lipids were extracted in chloroform/methanol (2:1,213
v/v) with vigorous shaking for 10 min. After centrifugation for 25 min at 1 200 g, the lower214
organic phase was collected, dried, and solubilized in chloroform:methanol. Lipid classes215
were separated by TLC on silica-gel plates by using petroleum ether/diethyl ether/acetic acid216
(85:15:0.5, v/v/v) as the mobile phase. Lipids were visualized with I2 vapour. Bands were217
scraped and TG were extracted from silica in chloroform:methanol. After centrifugation for218
45 min at 1 500 g to precipitate silica, and evaporation, TG were measured with PAP 150 TG219
kit (Biomerieux). Lipids droplets were detected in hepatocytes fixed with 3% (w/v)220
paraformaldehyde in PBS and colored with Oil red O [21].221
222
Measurement of ACC, FAS and malonyl-CoA decarboxylase (MCD) enzyme activity223
Cells were scrapped in ice cold 0.25 M saccharose, 1 mM DTT, 1 mM EDTA and protease224
inhibitors, and cytosolic fractions obtained by differential centrifugation (10 min, 10 000 g,225
then 1h, 100 000 g at 4°C) were used for ACC [22] and FAS activity [23] assay. MCD226
activity was assayed as described previously [24]227
228
Measurement of glucose metabolism229
During the last 24 h of culture, the medium was replaced by a medium containing either 5230
mM glucose or 20 mM glucose plus 10 nM insulin in the absence or presence of 200 M231
TOFA, a specific ACC inhibitor [25]. Glucose oxidation and glycogen synthesis were232
determined during the last 2 h of culture in the presence of either 5 mM [U-14C]D-glucose233
(133 Ci/mmol) or 20 mM [U-14C]D-glucose (87.5 Ci/mmol) plus 10 nM insulin, without or234
with 0.3 mM oleate bound to 1% (w/v) defatted BSA. After 2 h of incubation, the medium235
was collected to determine [14C]CO2 and unlabeled -hydroxybutyrate production, whereas236
cells were washed three times with ice-cold PBS and scraped in 1 ml 5N KOH. Cold237
glycogen carrier (2.5 mg) was added to the lysates (600 l) and samples were boiled for 30238
min. Glycogen was precipitated overnight at -20°C with two volumes of cold 100% ethanol.239
Precipitated glycogen was centrifuged at 10 000 g for 10 min. Pellets were washed once with240
70% ethanol, resuspended in 0.5 ml water, and counted by scintillation counting. Protein241
concentration was determined by Bradford method (BioRad) using BSA as a standard.242
Lipogenesis rate from 5 mM [1-14C]acetate (10 Ci per flask) was determined during the last243
2 h of culture as described previously [21]. Briefly, cells were rinsed twice with ice-cold PBS,244
immediately frozen in liquid nitrogen and scrapped off in 30% (v/v) KOH. Labeled fatty acids245
were then extracted and counted by scintillation counting.246
247
Measurement of mitochondrial activity248
MTS assay was performed in 12-well plates using the CellTiter 96 AQueous Non-Radioactive249
Cell Proliferation Assay (Promega) according to the manufacturer’s instructions.250
251
Statistical analysis252
Results are expressed as means ± S.E.M. Analysis of variance was carried out using StatView253
program (Abacus) to determine differences between groups. When significant differences254
were detected, a posteriori comparisons between means were conducted using the Fisher least255
significant difference (LSD) test ( = 0.05).256
257
258
259
260
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7RESULTS261
262
Adenovirus-mediated expression of CPT1wt and CPT1mt in rat hepatocytes263
To investigate whether an increase in CPT1A activity solely or in association with a264
decreased malonyl-CoA sensitivity could modulate hepatic LCFA oxidation, primary rat265
hepatocytes were infected with 2.5 or 5 ip/cell of adenovirus (Ad) encoding either wild-type266
rat CPT1A (CPT1wt) or mutant CPT1AM593S (CPT1mt) that is active but insensitive to267
malonyl-CoA inhibition [26-28]. This led to an increase in CPT1A protein expression in an268
adenovirus concentration dependent-manner in comparison to uninfected hepatocytes (Figure269
1a). The protein level of another enzyme of the mitochondrial carnitine-shuttle system, CPT2,270
whose activity is insensitive to malonyl-CoA inhibition [1], was not modified (Figure 1a). As271
a control, hepatocytes were also infected with an adenovirus encoding -galactosidase (gal).272
The resulting gal expression had no repercussion on CPT1A and CPT2 protein levels when273
compared to uninfected cells (Figure 1a). Considering these results, the amount of 5 ip/cell274
was chosen for subsequent infection experiments. Immunofluorescence analysis of infected275
hepatocytes showed that both overexpressed CPT1wt and CPT1mt proteins were colocalized276
with cytochrome c, a mitochondrial marker protein (Figure 1b), indicating as expected a277
mitochondrial localization. Moreover, infection with Ad-CPT1wt and Ad-CPT1mt278
respectively led to a 15- and 11-fold increase in mitochondrial CPT1A protein level and a 7-279
and 3-fold increase in CPT1A activity when compared to mitochondria isolated from either280
Ad-gal-infected or uninfected hepatocytes (Figure 2a). In agreement with Figure 1a, CPT1wt281
and CPT1mt overexpression had no repercussion on both mitochondrial CPT2 protein level282
and activity (Figure 2a).283
To evaluate the capacity of CPT1mt to exhibit enzyme activity despite the presence of284
malonyl-CoA, malonyl-CoA sensitivity was then measured in isolated mitochondria. In285
uninfected hepatocytes and Ad-gal- or Ad-CPT1wt-infected hepatocytes, CPT activity was286
almost completely suppressed (80%) by the highest malonyl-CoA concentration used (150287
µM) (Figure 2b). This was indicative of a good membrane integrity of the isolated288
mitochondria and suggested that only CPT1A activity was measured without any significant289
contribution of CPT2. Their corresponding IC50 values for malonyl-CoA were not290
significantly different (uninfected : 2.5 ± 0.7 M ; Ad-gal : 2.4 ± 0.6 M; Ad-CPT1wt : 12.2291
± 8.7 M). By contrast, in Ad-CPT1mt-infected hepatocytes, CPT1A activity was not292
inhibited by 1 to 10 M of malonyl-CoA (Figure 2b). Moreover, even in the presence of 150293
M of malonyl-CoA, only 43% of the activity was inhibited which likely corresponds to the294
inhibition of endogenous CPT1A. Altogether, these results confirm that CPT1wt and CPT1mt295
overexpression in rat hepatocytes increases mitochondrial CPT1A protein level and activity,296
CPT1mt being insensitive to malonyl-CoA inhibition.297
298
CPT1wt and CPT1mt overexpression counteracts glucose and insulin effects on lipid299
metabolism300
CPT1wt and CPT1mt overexpression in cultured rat hepatocytes increased LCFA ß-oxidation301
capacity under basal conditions of culture (5 mM glucose), leading to metabolic reorientation302
of exogenous LCFA toward oxidation at the expense of esterification (Supplementary Data303
1). We then evaluated their metabolic effects in the presence of high concentrations of304
glucose and insulin, conditions known to promote hepatic lipogenesis [10], hence preventing305
mitochondrial LCFA oxidation [1]. In uninfected hepatocytes, a 24 h-exposure to 20 mM306
glucose plus 10 nM insulin markedly stimulated the expression and the activity of lipogenic307
ACC and FAS enzymes (Supplementary Data 2a-c), de novo lipogenesis (see below Figure308
6b) and suppressed [1-
14
C]oleate oxidation by more than 90% (Figure 3a,b). Similar results309
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8were obtained in Ad-ßgal-infected hepatocytes. Overexpression of CPT1wt and CPT1mt did310
not alter the glucose/insulin-stimulated expression and activity of ACC and FAS, nor the311
enzymatic activity of malonyl-CoA decarboxylase (MCD) that catalyses the degradation of312
malonyl-CoA into acetyl-CoA (Supplementary Data 2). However, their overexpression led to313
a marked increase in [1-
14
C]oleate oxidation. Indeed, [
14
C]CO2 and [
14
C]acid-soluble product314
(ASP) productions were respectively increased by 4- and 6.8-fold for Ad-CPT1wt-infected315
hepatocytes and by 6.6- and 13.6-fold for Ad-CPT1mt-infected hepatocytes, when compared316
to Ad-gal-infected hepatocytes (Figure 3a,b). Conversely, only CPT1mt expression317
significantly decreased by 44% [1-
14
C]oleate esterification into TG when compared to Ad-318
gal-infected cells (Figure 3c), without any significant modification of its esterification into319
phospholipids (PL) (Figure 3d). In the presence of glucose and insulin, the total amount of [1-320
14
C]oleate metabolized was similar for all infections (uninfected : 103 ± 21; Ad-gal : 104 ±321
18; Ad-CPT1wt : 115 ± 12 and Ad-CPT1mt : 138 ± 17 nmol/2h/mg of prot). Whereas [1-322
14
C]oleate oxidation rate represented only 5% of [
14
C]oleate metabolized in Ad-gal-infected323
hepatocytes, CPT1wt and CPT1mt overexpression respectively increased this rate up to 30%324
and 47% (Figure 3e). To determine whether the decrease in [
14
C]TG production, and hence in325
esterification flux, was not due to an increased export of TG as VLDL, [1-
14
C]oleate326
incorporation into VLDL secreted into the culture medium was also measured. [1-
14
C]VLDL327
secretion was increased by 50% and 80% in hepatocytes overexpressing CPT1wt and328
CPT1mt, respectively (Figure 3f). However, the corresponding increased amount of329
incorporated oleate into VLDL (1.5 and 1.8 nmol/2h/mg of prot) was 10- and 20-fold lower330
than the observed reduction in oleate incorporation into TG (18 and 35 nmol/2h/mg of prot).331
Consequently, oleate incorporated into VLDL can likely explain no more than 10% of the332
decrease in TG esterification. Thus, in the presence of glucose and insulin, CPT1A333
overexpression decreased exogenous oleate esterification into TG by enhancing hepatic334
LCFA oxidation capacity, the effects of CPT1mt expression being always significantly higher335
than those observed for CPT1wt.336
To determine whether this decrease in exogenous oleate esterification was reflected in337
intracellular lipid content, Oil red O staining of hepatocytes, which allows visualization of338
neutral lipids within the cells, and measurement of intracellular TG content were performed.339
A 24 h-exposure to glucose and insulin induced in Ad-gal-infected cells a huge increase in340
lipid droplets, which was much lower in hepatocytes expressing CPT1mt (Figure 4a).341
Moreover, whereas the presence of glucose and insulin induced a 5-fold increase in TG342
content both in uninfected and Ad-gal-infected hepatocytes, CPT1mt expression decreased343
the TG content by 43% when compared to Ad-gal-infected hepatocytes (Figure 4b, left344
panel). CPT1wt overexpression led to an intermediate decrease in TG content (Figure 4b, left345
panel). In these culture conditions, cellular TG could result from esterification of both LCFA346
produced by de novo lipogenesis and exogenous oleate. To determine the contribution of TG347
coming from lipogenesis, intracellular TG were quantified after a 24 h-treatment with glucose348
and insulin, but in the absence of oleate. In these conditions, the TG content was also349
markedly increased in both uninfected and Ad-gal-infected hepatocytes (Figure 4b, right350
panel). CPT1wt and CPT1mt overexpression led to a respective 25% and 50% decrease in the351
glucose/insulin-stimulated TG accumulation when compared to Ad-gal-infected hepatocytes,352
with a significant difference between CPT1wt and CPT1mt (Figure 4b, right panel).353
Whatever the presence or not of exogenous oleate, the TG accumulation induced by glucose354
and insulin was not statistically different in hepatocytes infected with Ad-gal (Figure 4b).355
This indicated that accumulated cellular TG mostly resulted from esterification of LCFA356
newly synthetised from glucose. Thus, the increased capacity for LCFA oxidation due to357
CPT1wt and CPT1mt overexpression counteracts the glucose/insulin-induced accumulation of358
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9TG coming from lipogenesis.359
360
Effect of CPT1wt and CPT1mt overexpression on glucose metabolism361
To understand how the level of cellular TG resulting from lipogenesis could be decreased,362
two hypothesis were explored. The first one was that CPT1wt and CPT1mt overexpression363
could induce a decrease in glucose utilization, leading to a lower cellular TG content. To364
answer this question, [14C]glucose oxidation and [14C]glycogen synthesis were measured365
during the last 2 h of culture in the absence of exogenous oleate. As expected, glucose and366
insulin markedly stimulated glucose oxidation into CO2 and glycogen synthesis (Figure 5a,b,367
left panel). Infection of hepatocytes with either Ad-gal, Ad-CPT1wt or Ad-CPT1mt had no368
significant effect on [14C]CO2 production and [14C]glycogen synthesis (Figure 5a,b, left369
panels). A trend of decreased [14C]CO2 production was observed in hepatocytes infected with370
Ad-CPT1wt or Ad-CPT1mt. However, pyruvate, lactate, malate and oxaloacetate levels were371
not altered by CPT1wt and CPT1mt overexpression (data not shown). These results suggested372
that, in our experimental conditions, CPT1wt and CPT1mt overexpression did not alter373
glucose utilization. Similar results were observed in the presence of oleate (Figure 5a,b, right374
panels), indicating that, even when LCFA oxidation flux was further enhanced by addition of375
exogenous LCFA, glucose metabolism was also not altered.376
The second hypothesis was that CPT1wt and CPT1mt overexpression, which leads to an377
increase in LCFA oxidation capacity, might allow the oxidation of LCFA newly synthetised378
from glucose. To test this hypothesis, ß-hydroxybutyrate production was measured in379
hepatocytes cultured in the absence or presence of 0.3 mM oleate during the last 2 h of380
culture. As expected, in basal conditions of culture (5 mM glucose) and in the absence of381
exogenous oleate, ß-hydroxybutyrate level remained low in uninfected hepatocytes whereas it382
increased by 2.8-fold upon oleate addition (Figure 6a). In uninfected and Ad-gal-infected383
hepatocytes, a 24 h-exposure to glucose and insulin decreased ß-hydroxybutyrate production384
to the same basal level whatever the presence or not of oleate (Figure 6a). By contrast, in the385
presence of oleate, ß-hydroxybutyrate level respectively increased by 2.5- and 3.2-fold in386
CPT1wt and CPT1mt overexpressing hepatocytes, hence abrogating the glucose/insulin387
inhibitory effect on ketogenesis (Figure 6a, right panel). The observation that a 1.7-fold388
(CPT1wt) and 2.3-fold (CPT1mt) increase in ß-hydroxybutyrate production occurred in the389
absence of exogenous oleate (Figure 6a, left panel) strongly suggested that LCFA arising390
from lipogenesis are oxidized to produce ketone bodies. To confirm this, hepatocytes were391
cultured for 24 h in the presence of TOFA, a specific ACC inhibitor [25]. As expected, TOFA392
treatment of uninfected hepatocytes totally inhibited both basal and glucose/insulin-stimulated393
de novo lipogenesis (Figure 6b) as well as glucose/insulin-induced TG accumulation (Figure394
6c). In these conditions, the increase in ß-hydroxybutyrate production previously observed in395
CPT1wt and CPT1mt overexpressing hepatocytes was fully abrogated (Figure 6a), confirming396
that the produced ß-hydroxybutyrate arised from the oxidation of de novo synthetised LCFA.397
Thus, the higher induced increase in ß-hydroxybutyrate production observed in the presence398
of exogenous oleate (Figure 6a) resulted from the oxidation of both exogenous and de novo399
synthetised LCFA. As observed previously, CPT1mt expression had, both in the absence and400
presence of oleate, a significantly higher effect than CPT1wt overexpression. Altogether,401
these results indicate that the observed decrease in cellular TG content in the absence of402
exogenous LCFA (Figure 4b) is not due to an alteration in glucose utilization following403
CPT1wt or CPT1mt overexpression, but results from the oxidation of LCFA newly404
synthetised from glucose.405
406
407
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10
DISCUSSION408
409
The present study provides the first proof of concept that, even in conditions under which410
lipogenesis is stimulated, a direct modulation of the malonyl-CoA/CPT1A partnership in liver411
cells is a relevant strategy to maintain a high mitochondrial LCFA ß-oxidation flux which412
protects against TG accumulation.413
In agreement with previous in vitro studies performed in pancreatic ß-cells [27], muscle414
cells [29] and hepatocytes [9], the present study showed that overexpression of rat CPT1wt or415
expression of CPT1mt in cultured rat hepatocytes increased LCFA ß-oxidation capacity under416
basal conditions of culture. To challenge whether this increased oxidative capacity could be417
maintained in conditions under which LCFA ß-oxidation is usually abolished, we chose to418
expose primary cultured rat hepatocytes to 20 mM glucose plus 10 nM insulin, conditions419
known to elicit hepatic lipogenesis [10]. As expected, this markedly increased glucose420
oxidation and glycogen synthesis, stimulated ACC and FAS expression and enzymatic421
activity as well as de novo lipogenesis, and led to TG accumulation, whereas it abolished422
exogenous oleate oxidation and ketogenesis. We presently showed that CPT1A423
overexpression partially (CPT1wt) or fully (CPT1mt) abolished the inhibitory effect of424
glucose/insulin on oleate oxidation. This allowed, in the case of CPT1mt expression, the425
maintenance of an oxidation flux and a ketone body production from exogenous LCFA426
similar to those observed in basal conditions of culture. It is noteworthy that this was427
accomplished without alteration in the stimulatory effects of glucose/insulin on lipogenic428
enzymes expression and activity and on glucose utilization. Moreover, the higher429
effectiveness of CPT1mt than CPT1wt overexpression to counteract the glucose/insulin430
effects on hepatic lipid metabolism occurred despite a lower increase in both mitochondrial431
CPT1A protein level and activity. The biological relevance of this finding is that it represents432
the converse experimental demonstration of McGarry’s discovery of the physiological role of433
malonyl-CoA in controlling hepatic LCFA metabolic fate [1-3]. Although liver mitochondrial434
glycerol-3-phosphate acyltransferase 1 isoform, which catalyzes the first step in glycerolipid435
synthesis, may be important for LCFA metabolic channeling by competing with CPT1A for436
cytosolic LC-CoAs [30,31], our data clearly demonstrated that control of CPT1A activity by437
malonyl-CoA is an essential driving force for exogenous LCFA ß-oxidation flux.438
Additionally, they strengthened our prior findings that changes in the degree of CPT1A439
malonyl-CoA sensitivity, which occur in vivo in different physiopathological situations [11-440
15], play a critical role in the regulation of hepatic LCFA oxidation flux [19,32]. Therefore,441
this observation let us to predict that strategies aiming to increase only CPT1A activity might442
be limited in situations where malonyl-CoA levels remain high. This may explain why a443
compensatory increase in CPT1A gene expression might be insufficient to prevent hepatic TG444
accumulation when lipogenesis is exacerbated such as in mice overexpressing acyl-445
CoA:diacylglycerol acyltransferase 2 in the liver [33].446
The key finding of our study is that, in the absence of exogenous LCFA, CPT1mt447
expression still markedly protects liver cells from glucose/insulin-induced TG accumulation.448
In these culture conditions, TG can only be produced by esterification of LCFA de novo449
synthetised from glucose through lipogenesis. By deciphering the metabolic impact of450
CPT1mt expression, we clearly showed that the decreased TG content directly resulted from451
ß-oxidation of the newly synthetised LCFA as reflected by the increased ß-hydroxybutyrate452
production. Thus, an increased CPT1A activity in association with a decreased malonyl-CoA453
sensitivity allowed hepatocytes to oxidize LCFA whatever their origin i.e. exogenous or454
endogenous (Figure 7). According to the Randle’s glucose/fatty acid cycle, one would predict455
that increased LCFA ß-oxidation may have an effect on the metabolic fate of glucose [34].456
However, previous studies reported that CPT1wt and CPT1mt overexpression did not affect457
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11
glucose metabolism in pancreatic ß-cells [27] and in muscular cells [28]. Similarly, in the458
present study, an increased LCFA ß-oxidation flux in hepatocytes did not altered the insulin-459
induced glucose oxidation and glycogen synthesis. Additionally, oxidation of both glucose460
and LCFA is associated with conversion of oxidized cofactors into reduced cofactors which461
are then re-oxidized by the mitochondrial respiratory chain in order to permit other cycles of462
fuel oxidation [35]. The lactate/pyruvate and ß-hydroxybutyrate/acetoacetate ratio463
respectively reflect the cytosolic and mitochondrial NADH/NAD
+
ratio. In the presence of464
glucose plus insulin, CPT1wt and CPT1mt overexpression did not modify the lactate/pyruvate465
ratio, suggesting no alteration in the cytosolic redox state. ß-hydroxybutyrate/acetoacetate466
ratio increased upon CPT1wt and CPT1mt overexpression but did not exceed the one467
measured in basal conditions of culture (data not shown). Moreover, the mitochondrial468
activity reflected by a MTS assay was not modified by CPT1wt and CPT1mt overexpression469
(Supplementary Data 3). This suggests that mitochondria, in our experimental conditions, are470
able to handle efficiently the re-oxidation of NADH when both glucose and LCFA are471
oxidized. As illustrated in the present study, the fundamental role of the hepatic malonyl-472
CoA/CPT1A partnership is to provide a powerful regulatory mechanism for metabolic switch473
between carbohydrate and lipid utilization as energy fuel. Presently, we report for the first474
time that the malonyl-CoA/CPT1A interaction is also essential to preserve the cells from475
wasting energy by diverting the newly de novo synthetised LCFA from mitochondrial476
oxidation (Figure 7). This may greatly contribute to the physiological function of the liver to477
convert excess dietary carbohydrates into TG.478
Because hepatic steatosis is a risk factor for nonalcoholic steatohepatitis and type 2479
diabetes, research efforts have focused on a decreased capacity for de novo lipogenesis in an480
attempt to prevent and/or reduce hepatic steatosis. Among them, liver-specific suppression of481
rat ACC isoforms expression [36], inhibition of the nuclear factor carbohydrate responsive482
element binding protein gene expression [37], which decreased ACC and FAS gene483
expression, and hepatic MCD overexpression [38] were effective in decreasing TG content in484
fed animals and/or hepatic steatosis and insulin resistance in obese animals. Due to the485
existence of the malonyl-CoA/CPT1A partnership, these strategies also stimulated LCFA ß-486
oxidation flux through the release of CPT1A from malonyl-CoA inhibition [36-38]. Direct487
evidence that an enhanced capacity to oxidize LCFA per se, independently of a reduced488
lipogenesis flux, may contribute to decrease liver TG content was recently provided by in vivo489
overexpression of wild-type CPT1A in rat liver [9]. However, in high-fat diet-induced obese490
rats, hepatic CPT1A overexpression led only to a slight increase in LCFA ß-oxidation491
capacity and a substantial reduction in hepatic TG accumulation whereas no improvement of492
insulin sensitivity could be observed [9]. Such moderate effects might be due to the presence493
of elevated malonyl-CoA concentration which, despite an increased CPT1A expression, can494
limit in vivo CPT1A activity since the latter remains malonyl-CoA sensitive. Therefore, we495
propose that, in addition to an increase in CPT1A expression, acting directly on the degree of496
CPT1A malonyl-CoA sensitivity, might be a more relevant strategy in situations of insulin497
resistance which are associated with an increase in LCFA delivery to the liver (increased498
consumption of a high-fat diet and/or lipolysis) and in endogenous LCFA (excessive499
lipogenesis).500
In summary, a direct modulation of malonyl-CoA/CPT1A interaction in liver cells,501
independently of the lipogenic pathway, allows mitochondrial oxidation of both exogenous502
LCFA taken up by the liver and endogenous LCFA generated by lipogenesis, without503
alteration in glucose utilization. Thus, whereas CPT1A inhibition by malonyl-CoA is essential504
to avoid in physiological situations a waste of energy, modulation of its malonyl-CoA505
sensitivity may be a useful therapeutic strategy to prevent and/or reduce liver steatosis.506
507
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657
FOOTNOTES658
Abbreviations used: CPT1, carnitine palmitoyltransferase 1; CPT1A, liver isoform of CPT1;659
LCFA, long-chain fatty acid; LC-CoA, long-chain acyl-CoA; ACC, acetyl-CoA carboxylase;660
FAS, fatty acid synthase; TG, triglyceride; VLDL, very-low-density lipoprotein; TOFA, 5-661
(Tetradecyloxy)-2-furoic acid; Ad, adenovirus; gal, -galactosidase; CPT1wt, wild-type rat662
CPT1A; CPT1mt, mutant CPT1AM593S; ip, infectious particules; CPT2, carnitine663
palmitoyltransferase 2; ASP, acid-soluble product; PL, phospholipids; MCD, malonyl-CoA664
decarboxylase.665
666
667
668
LEGENDS TO FIGURES669
Figure 1. Mitochondrial localization of the overexpressed CPT1wt and CPT1mt proteins670
in cultured rat hepatocytes671
Primary rat hepatocytes were infected with either 0, 2.5 or 5 ip/cell of the indicated672
adenovirus and cultured for 40 h in 5 mM glucose. (a) Immunoblot analysis of cellular673
extracts (30 µg of protein) using specific antibodies for -galactosidase (gal), CPT1A and674
CPT2. Western blots are representative of four independent experiments performed in675
duplicates. (b) Immunofluorescence analysis detection of the overexpressed CPT1 proteins.676
Hepatocytes were double-immunostained with antibodies raised against cytochrome c (Cyt c)677
and CPT1A. The right panels (merge) represent the overlay of the two left panels.678
Colocalization of cytochrome c and CPT1A appears as yellow spots reflecting the merge of679
red (Cyt c) and green (CPT1A) fluorescence. Hoechst 33342 was used to stain the hepatocyte680
nuclei. The bar represents 50 m.681
682
Figure 2. Effects of CPT1wt and CPT1mt overexpression on CPT1A protein level and683
activity (a) and malonyl-CoA sensitivity (b) in mitochondria isolated from infected684
hepatocytes685
Mitochondria were isolated 40 h after infection of hepatocytes with 5 ip/cell of the indicated686
adenovirus. (a) Immunoblot analysis of mitochondrial protein using specific antibodies for687
CPT1A and CPT2. Western blots are representative of three independent experiments with688
mitochondria isolated from separate hepatocytes cultures. CPT1A and CPT2 activities were689
measured in either intact (CPT1A) or solubilized (CPT2) mitochondria. Results are mean ±690
S.E.M. of three independent experiments with separate isolated mitochondria. (b) Malonyl-691
CoA sensitivity of CPT1A was measured in intact isolated mitochondria. Results are mean ±692
S.E.M. of two independent experiments with separate isolated mitochondria. * P < 0.01 vs.693
Ad-gal; # P < 0.01.694
695
Figure 3. CPT1wt and CPT1mt overexpression counteracts the glucose/insulin effects on696
[1-14C]oleate metabolism697
Sixteen hours after infection of hepatocytes with 5 ip/cell of the indicated adenovirus, cells698
were cultured for 24 h in the presence of either 5 mM glucose (G5) or 20 mM glucose plus 10699
nM insulin (G20 + ins). During the last 2 h of culture, 0.3 mM [1-14C]oleate bound to 1%700
defatted BSA was added. Oleate oxidation into CO2 (a) and acid-soluble products (ASP) (b),701
and oleate esterification into cellular triglycerides (TG) (c) and phospholipids (PL) (d) were702
measured at the end of the 2 h-incubation period. (e) Metabolic orientation of oleate as a703
percentage of the total nmol of metabolized [1-14C]oleate. (f) [1-14C]Oleate incorporation into704
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very-low-density lipoprotein (VLDL) secreted in the culture medium during the 2 h705
incubation period. Results are mean ± S.E.M. of duplicate flasks from four independent706
experiments. * P < 0.05 and ** P < 0.01 vs. Ad-gal; # P < 0.05.707
708
Figure 4. CPT1mt overexpression decreases the glucose/insulin-induced TG709
accumulation in cultured hepatocytes710
Sixteen hours after infection with 5 ip/cell of the indicated adenovirus, hepatocytes were711
cultured for 24 h in the presence of either G5 or G20 + ins. (a) Oil red O staining of712
hepatocytes to detect neutral lipid droplets. Oleate (0.3 mM) was added during the last 2 h of713
culture. Original magnification, X 200. (b) Measurement of cellular TG content. When714
indicated, 0.3 mM oleate was added during the last 2 h of culture. Results are mean ± S.E.M.715
of duplicate flasks from three independent experiments. * P < 0.05 and ** P < 0.01 vs. Ad-716
gal in G20 + ins; # P < 0.05.717
718
Figure 5. CPT1wt and CPT1mt overexpression does not alter the glucose/insulin effects719
on [U-14C]glucose metabolism720
Sixteen hours after infection with 5 ip/cell of the indicated adenovirus, hepatocytes were721
cultured for 24 h in the presence of either G5 or G20 + ins. During the last 2 h, a tracer722
amount of [U-14C]glucose was added in the absence or in the presence of 0.3 mM oleate. The723
medium was then collected to measure [U-14C]glucose oxidation into CO2 (a). Cells were724
washed and scrapped to measure incorporation of [U-14C]glucose into glycogen (b). Results725
are mean ± S.E.M. of duplicate flasks from five independent experiments. § P < 0.01 vs. G5.726
727
Figure 6. CPT1wt and CPT1mt overexpression allows oxidation of de novo synthetised728
LCFA729
Sixteen hours after infection with 5 ip/cell of the indicated adenovirus, hepatocytes were730
cultured for 24 h in the presence of either G5 or G20 + ins, in the absence or presence of 200731
M 5-(Tetradecyloxy)-2-furoic acid (TOFA). When indicated, 0.3 mM oleate was added732
during the last 2 h of culture. (a) The medium was collected to measure -hydroxybutyrate733
production. (b) The lipogenesis rate from 5 mM [1-14C]acetate was measured, in the absence734
of exogenous oleate, in uninfected cells during the last 2 h of culture. (c) Measurement of735
cellular TG content. Results are mean ± S.E.M. of duplicate flasks from three to seven736
independent experiments. † P < 0.01 vs. without oleate; * P < 0.05 and ** P < 0.01 vs. Ad-737
gal in G20 + ins; # P < 0.01.738
739
Figure 7. Importance of the malonyl-CoA/CPT1A partnership in the liver740
In physiological situations, inhibition of CPT1A by malonyl-CoA preserves liver cells from741
wasting energy by preventing ß-oxidation of long-chain fatty acids (LCFA) de novo742
synthetised from glucose. Indeed, retrieving CPT1A from malonyl-CoA inhibition743
(expression of a malonyl-CoA-insensitive CPT1A i.e. CPT1mt) induces a metabolic switch744
toward ß-oxidation of LCFA independently of their origin (exogenous or de novo745
synthetised), and prevents triglycerides (TG) accumulation in liver cells. Therefore, malonyl-746
CoA/CPT1A partnership greatly contributes to the physiological function of the liver to747
convert excess dietary carbohydrates into TG.748
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